Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: Evidence and reason

Pediatric Cardiology

Volumn 33, Issue 3, 2012, Pages 394-401

  Batra, Anjan S ^a   Alexander, Mark E ^b   Silka, Michael J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Attention deficit hyperactivity disorder; Congenital heart disease; Stimulant medications; Sudden death

Indexed keywords

AMPHETAMINE; ATOMOXETINE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT;

ATTENTION DEFICIT DISORDER; BRAIN INJURY; CARDIOVASCULAR RISK; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY HEMODYNAMICS; DIASTOLIC BLOOD PRESSURE; DIGEORGE SYNDROME; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FALLOT TETRALOGY; HEART ARREST; HEART ATRIUM SEPTUM DEFECT; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; LONG QT SYNDROME; PR INTERVAL; PRACTICE GUIDELINE; PREVALENCE; QRS COMPLEX; QT INTERVAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; VELOCARDIOFACIAL SYNDROME; CONGENITAL HEART MALFORMATION; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; PATHOLOGY; UNITED STATES;

AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; EVIDENCE-BASED MEDICINE; HEART DEFECTS, CONGENITAL; HUMANS; METHYLPHENIDATE; UNITED STATES;

EID: 84862669984     PISSN: 01720643     EISSN: 14321971     Source Type: Journal    
DOI: 10.1007/s00246-012-0162-6     Document Type: Review

References (27)

1. Alexander M et al (2011) PACES survey. Presented at the HRS annual meeting
2. American Academy of Pediatrics, Steering Committee on Quality Improvement and Management (2004) Classifying recommendations for clinical practice guidelines. Pediatrics 114:874-877
3. Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, Weber KJ, Mrazek DA, Jacobsen SJ (2002) How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minnesota. Arch Pediatr Adolesc Med 156:217-224 (Pubitemid 34205431)
4. Berger S, Campbell R, Drezner J (2009) PACES survey. http://www. pediatricepsociety.org/links/. Accessed Sep 2011
5. Biederman J, Lopez FA, Boellner SW, Chandler MC (2002) A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/ hyperactivity disorder. Pediatrics 110:258-266 (Pubitemid 34833008)
6. Brown RT, Freeman WS, Perrin JM, Stein MT, Amler RW, Feldman HM, Pierce K, Wolraich ML (2001) Prevalence and assessment of attention-deficit/ hyperactivity disorder in primary care settings. Pediatrics 107:E43
7. Conway J, Wong KK, O'Connell C, Warren AE (2008) Cardiovascular risk screening before starting stimulant medications and prescribing practices of Canadian physicians: impact of the Health Canada Advisory. Pediatrics 122:e828-e834
8. Findling RL, Short EJ, Manos MJ (2001) Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry 40:525-529 (Pubitemid 32374269)
9. Findling RL, Biederman J, Wilens TE, Spencer TJ, McGough JJ, Lopez FA, Tulloch SJ (2005) Short-and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 147:348-354 (Pubitemid 41348714)
10. Gothelf D, Gruber R, Presburger G, Dotan I, Brand-Gothelf A, Burg M, Inbar D, Steinberg T, Frisch A, Apter A, Weizman A (2003) Methylphenidate treatment for attention-deficit/hyper-activity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry 64:1163-1169
11. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992-1001
12. Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R, Taubert KA (1999) AHA scientific statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. Circulation 99:979-982
13. Health Canada (2006) Search page. www.hc-sc.gc.ca/dhp-mps/medeff/ advisories-avis/prof/-2006/adhd-tdah-medic-hpc-cps-eng.php. Accessed Sep 2011
14. Hoffman JI, Kaplan S, Liberthson RR (2004) Prevalence of congenital heart disease. Am Heart J 147:425-439 (Pubitemid 38880862)
15. Kirshbom PM, Flynn TB, Clancy RR, Ittenbach RF, Hartman DM, Paridon SM, Wernovsky G, Spray TL, Gaynor JW (2005) Late neurodevelopmental outcomes after repair of total anomalous pulmonary venous connections. J Thorac Cardiovasc Surg 129:1091-1096
16. Mahle WT, Clancy RR, Moss EM, Gerdes M, Jobes DR, Wer-novsky G (2000) Neurodevelopmental outcome and lifestyle assessment in school-aged and adolescent children with hypo-plastic left heart syndrome. Pediatrics 105:1082-1089 (Pubitemid 30243787)
17. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC (2009) Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents, and young adults using the general practice research database. Drug Saf 32:1089-1096
18. Perrin JM, Friedman RA, Knilans TK (2008) Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 122:451-453
19. Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S (2011) Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 127:1102-1110
20. Shillingford AJ, Glanzman MM, Ittenbach RF, Clancy RR, Gaynor JW, Wernovsky G (2008) Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease. Pediatrics 121:e759-e767
21. U.S. Food and Drug Administation (2007) FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events. http://www.fda.gov/bbs/topics/news/2007/new01568. html. Accessed Sep 2011
22. U.S. Food and Drug Administration (2005) Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). http://www.fda.gov/medwatch/safety/2005/aug05.htm. Accessed Sep 2011
23. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL (2008) Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/ hyperactivity disorder (corrected): a scientific statement from the American heart association council on cardiovascular disease in the young congenital cardiac defects committee and the council on cardiovascular nursing. Circulation 117:2407-2423 (Pubitemid 351653546)
24. Warren AE, Hamilton RM, Bélanger SA, Gray C, Gow RM, Sanatani S, Cǒté JM, Lougheed J, LeBlanc J, Martin S, Miles B, Mitchell C, Gorman DA, Weiss M, Schachar R (2009) Cardiac risk assessment before the use of stimulant medications in children and youth: a joint position statement by the Canadian pae-diatric society, the Canadian cardiovascular society, and the Canadian academy of child and adolescent psychiatry. Can J Cardiol 25:625-630
25. Wigal SB, Chae S, Patel A, Steinberg-Epstein R (2010) Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. Semin Pediatr Neurol 17: 230-236
26. Wilens TE, Prince JB, Spencer TJ, Biederman J (2006) Stimulants and sudden death: what is a physician to do? Pediatrics 118:1215-1219 (Pubitemid 46090066)
27. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G (2001) Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 108:883-892 (Pubitemid 32947657)